Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Co-authors
(200)
Manfred Kaufmann
30
Gunter von Minckwitz
28
Bernd Gerber
23
Jorn Hilfrich (Jörn Hilfrich)
18
Christian Jackisch
16
Journals
(28)
ZBL GYNAKOL
7
EUR J CANCER
4
ANN ONCOL
3
BREAST CANCER RES TREAT
3
EJC SUPPL
3
Keywords
(103)
Embed
Subscribe
Academic
Authors
Serban Dan Costa
Serban Dan Costa,Otto von Guericke University Magdeburg,Oncology,Anatomy,Dermatology
Edit
Serban Dan Costa
Otto von Guericke University Magdeburg
Publications:
57
|
Citations:
893
Fields:
Oncology
,
Anatomy
,
Dermatology
View FAQ about top research areas and Fields of study
Collaborated with
200 co-authors
from 1991 to 2011
|
Cited by
3272 authors
Cumulative
Annual
Sort by:
Publications
(57)
BibTeX
|
RIS
|
RefWorks
Download
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
(
Citations: 4
)
Gunter von Minckwitz
,
Michael Untch
,
Eveline Nüesch
,
Sibylle Loibl
,
Manfred Kaufmann
,
Sherko Kümmel
,
Peter A. Fasching
,
Wolfgang Eiermann
,
Jens-Uwe Blohmer
,
Serban Dan Costa
,
Keyur Mehta
,
Jörn Hilfrich
http://academic.research.microsoft.com/io.ashx?type=5&id=47597124&selfId1=21138959&selfId2=0&maxNumber=12&query=
Journal:
Breast Cancer Research and Treatment - BREAST CANCER RES TREAT
, vol. 125, no. 1, pp. 145-156, 2011
G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer
Tanja Ignatov
,
Christine Weißenborn
,
Holm Eggemann
,
Joachim Bischoff
,
Andrzej Semczuk
,
Albert Roessner
,
Serban Dan Costa
,
Thomas Kalinski
Journal:
Breast Cancer Research and Treatment - BREAST CANCER RES TREAT
, vol. 128, no. 2, pp. 457-466, 2011
Neoadjuvant Treatment With Trastuzumab in HER2Positive Breast Cancer: Results From the GeparQuattro Study
(
Citations: 19
)
M. Untch
,
M. Rezai
,
S. Loibl
,
P. A. Fasching
,
J. Huober
,
H. Tesch
,
I. Bauerfeind
,
J. Hilfrich
,
H. Eidtmann
,
B. Gerber
,
C. Hanusch
,
T. Kuhn
S. Dan Costa
http://academic.research.microsoft.com/io.ashx?type=5&id=30853419&selfId1=21138959&selfId2=0&maxNumber=12&query=
Journal:
Journal of Clinical Oncology - J CLIN ONCOL
, vol. 28, no. 12, pp. 2024-2031, 2010
Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study
(
Citations: 14
)
G. von Minckwitz
,
M. Rezai
,
S. Loibl
,
P. A. Fasching
,
J. Huober
,
H. Tesch
,
I. Bauerfeind
,
J. Hilfrich
,
H. Eidtmann
,
B. Gerber
,
C. Hanusch
,
T. Kuhn
S. Dan Costa
http://academic.research.microsoft.com/io.ashx?type=5&id=30853355&selfId1=21138959&selfId2=0&maxNumber=12&query=
Journal:
Journal of Clinical Oncology - J CLIN ONCOL
, vol. 28, no. 12, pp. 2015-2023, 2010
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
(
Citations: 4
)
G. von Minckwitz
,
H. Eidtmann
,
S. Loibl
,
J.-U. Blohmer
,
S.-D. Costa
,
P. A. Fasching
,
R. Kreienberg
,
J. Hilfrich
,
B. Gerber
,
C. Hanusch
,
T. Fehm
,
D. Strumberg
http://academic.research.microsoft.com/io.ashx?type=5&id=28888128&selfId1=21138959&selfId2=0&maxNumber=12&query=
Journal:
Annals of Oncology - ANN ONCOL
, vol. 21, no. 8, 2010
Sort by:
Citations
(893 times by 793 publications)
Alternate Estrogen Receptors Promote Invasion of Inflammatory Breast Cancer Cells via Non-Genomic Signaling
Kazufumi Ohshiro
,
Arnold M. Schwartz
,
Paul H. Levine
,
Rakesh Kumar
Journal:
PLOS One
, vol. 7, no. 1, 2012
Breast cancerNeoadjuvant bevacizumab treatment—signal or noise?
Harold J. Burstein
Journal:
Nature Reviews Clinical Oncology - NAT REV CLIN ONCOL
, vol. 9, no. 4, pp. 191-192, 2012
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
(
Citations: 4
)
Gunter von Minckwitz
,
Michael Untch
,
Eveline Nüesch
,
Sibylle Loibl
,
Manfred Kaufmann
,
Sherko Kümmel
,
Peter A. Fasching
,
Wolfgang Eiermann
,
Jens-Uwe Blohmer
,
Serban Dan Costa
,
Keyur Mehta
,
Jörn Hilfrich
http://academic.research.microsoft.com/io.ashx?type=5&id=47597124&selfId1=21138959&selfId2=0&maxNumber=12&query=
Journal:
Breast Cancer Research and Treatment - BREAST CANCER RES TREAT
, vol. 125, no. 1, pp. 145-156, 2011
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
(
Citations: 2
)
A. Noske
,
S. Loibl
,
S. Darb-Esfahani
,
M. Roller
,
R. Kronenwett
,
B. M. Müller
,
J. Steffen
,
C. von Toerne
,
R. Wirtz
,
I. Baumann
,
G. Hoffmann
,
G. Heinrich
http://academic.research.microsoft.com/io.ashx?type=5&id=48207915&selfId1=21138959&selfId2=0&maxNumber=12&query=
Journal:
Breast Cancer Research and Treatment - BREAST CANCER RES TREAT
, vol. 126, no. 1, pp. 109-117, 2011
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review
(
Citations: 1
)
José A. García-Sáenz
,
Ana Custodio
,
Antonio Casado
,
José Antonio Vidart
,
Pluvio J. Coronado
,
Miguel Martín
,
Sara López-Tarruella
,
Javier Puente
,
Cristina Fernández
,
Eduardo Díaz-Rubio
Journal:
Clinical & Translational Oncology - CLIN TRANSL ONCOL
, vol. 13, no. 2, pp. 121-132, 2011
Comments